United Therapeutics Corporation $UTHR Stock Holdings Trimmed by Moody National Bank Trust Division

Moody National Bank Trust Division lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 36.8% in the fourth quarter, HoldingsChannel reports. The fund owned 2,140 shares of the biotechnology company’s stock after selling 1,248 shares during the period. Moody National Bank Trust Division’s holdings in United Therapeutics were worth $1,043,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. AE Wealth Management LLC raised its position in shares of United Therapeutics by 396.3% during the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after buying an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC lifted its stake in shares of United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after acquiring an additional 2,975 shares during the period. Optimize Financial Inc bought a new position in shares of United Therapeutics in the third quarter valued at approximately $444,000. Simplify Asset Management Inc. acquired a new position in shares of United Therapeutics during the third quarter valued at approximately $8,351,000. Finally, Osaic Holdings Inc. raised its holdings in United Therapeutics by 271.0% during the second quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after purchasing an additional 33,662 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research analyst reports. Cantor Fitzgerald upped their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. HC Wainwright boosted their price objective on United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. TD Cowen upped their price objective on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, UBS Group lifted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $549.91.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Several brokerages have lifted price targets and reiterated buy/outperform views (examples cited include HC Wainwright, RBC, Cantor Fitzgerald and UBS), supporting upside expectations and helping sentiment. Analyst Coverage Summary
• Positive Sentiment: Wells Fargo published a bullish forecast for UTHR, calling for meaningful price appreciation and adding directional support to the tape. Wells Fargo Research
• Positive Sentiment: Recent quarterly results showed EPS outperformance versus consensus (EPS beat), underpinning the fundamental case even as revenue slightly missed; analysts’ upward revisions follow those results. Quarterly Results Summary
• Neutral Sentiment: Brokerage consensus remains a “Moderate Buy” — constructive but not unanimous; this keeps expectations elevated but measured. Analyst Consensus
• Neutral Sentiment: Institutional ownership is high and several funds reported increasing stakes in recent quarters, which can support liquidity and reduce volatility. Institutional Holdings
• Negative Sentiment: Insider selling: CEO Martine Rothblatt sold 9,500 shares (~$5.0M) and CFO James Edgemond sold 10,000 shares (~$5.27M) in March; large officer sales can pressure sentiment even if company says sales are routine. SEC filings: CEO sale CEO SEC Filing, CFO sale CFO SEC Filing
• Neutral Sentiment: Short-interest reports in recent feeds show data anomalies (zero reported shares / NaN changes) and are not providing a clear short-squeeze or bearish signal at this time. Short Interest Data

United Therapeutics Stock Up 1.8%

Shares of NASDAQ UTHR opened at $541.60 on Thursday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $549.50. The company has a market cap of $23.74 billion, a price-to-earnings ratio of 19.41, a P/E/G ratio of 1.92 and a beta of 0.84. The business has a fifty day simple moving average of $493.58 and a 200-day simple moving average of $471.33.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter last year, the business posted $6.19 EPS. United Therapeutics’s revenue was up 7.4% on a year-over-year basis. As a group, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $489.91, for a total transaction of $4,654,145.00. Following the sale, the chief executive officer owned 130 shares in the company, valued at $63,688.30. The trade was a 98.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. This trade represents a 34.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 336,820 shares of company stock valued at $166,359,058 over the last ninety days. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.